We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$206M
AUM Growth
+$19.9M
Cap. Flow
-$6.78M
Cap. Flow %
-3.3%
Top 10 Hldgs %
45.09%
Holding
85
New
12
Increased
15
Reduced
25
Closed
10

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$11.1M
2
STXS icon
Stereotaxis
STXS
+$8.18M
3
AKBA icon
Akebia Therapeutics
AKBA
+$6.64M
4
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.93M
5
LMNX
Luminex Corp
LMNX
+$4.14M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$12.2M
2
ONC
BeOne Medicines Ltd
ONC
+$7.32M
3
ARGX icon
argenx
ARGX
+$2.81M
4
VYGR icon
Voyager Therapeutics
VYGR
+$2.61M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.55M

Sector Composition

Rank Sector Weight
1 Healthcare 86.28%
2 Financials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
26
Kura Oncology
KURA
$800M
$2.38M 1.16%
127,000
+9,719
+8% +$189K
SCYX icon
27
SCYNEXIS
SCYX
$48.1M
$2.19M 1.07%
20,461
+14,125
+223% +$1.95M
BEAT
28
DELISTED
BioTelemetry, Inc.
BEAT
$2.16M 1.05%
69,500
-18,600
-21% -$612K
MGNX icon
29
MacroGenics
MGNX
$235M
$2.09M 1.02%
83,105
-71,095
-46% -$1.73M
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.06B
$1.85M 0.9%
377,695
– –
WVE icon
31
Wave Life Sciences
WVE
$1.09B
$1.78M 0.87%
+44,400
New +$1.87M
FOMX
32
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.72M 0.84%
335,500
-17,241
-5% -$104K
CYPH
33
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.66M 0.81%
20,000
+9,167
+85% +$631K
AGTC
34
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.62M 0.79%
421,000
– –
CMTA
35
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.59M 0.77%
105,000
+45,000
+75% +$732K
NGNE icon
36
Neurogene
NGNE
$656M
$1.52M 0.74%
5,396
-550
-9% -$152K
ARQL
37
DELISTED
Arqule Inc
ARQL
$1.4M 0.68%
484,984
-212,208
-30% -$403K
NTUS
38
DELISTED
Natus Medical Inc
NTUS
$1.27M 0.62%
37,900
+30,000
+380% +$949K
KA
39
DELISTED
Kineta, Inc. Common Stock
KA
$1.27M 0.62%
1,908
+1,069
+127% +$645K
ARDX icon
40
Ardelyx
ARDX
$1.22B
$1.25M 0.61%
247,859
-27,200
-10% -$170K
INCY icon
41
Incyte
INCY
$24.2B
$1.25M 0.61%
+15,000
New +$1.35M
ONC
42
BeOne Medicines Ltd
ONC
$32.8B
$1.23M 0.6%
7,330
-54,019
-88% -$7.32M
JNJ icon
43
Johnson & Johnson
JNJ
$618B
$1.21M 0.59%
9,400
– –
CGNT
44
DELISTED
Cogentix Medical, Inc.
CGNT
$1.2M 0.58%
310,382
-13,100
-4% -$41K
ADXS
45
DELISTED
Advaxis Inc
ADXS
$1.18M 0.57%
46,467
+30,000
+182% +$1.12M
TVRD
46
Tvardi Therapeutics
TVRD
$19.7M
$1.16M 0.56%
2,606
– –
IMDZ
47
DELISTED
Immune Design Corp.
IMDZ
$1.08M 0.53%
328,500
– –
NERV icon
48
Minerva Neurosciences
NERV
$185M
$1.07M 0.52%
21,387
– –
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.02M 0.49%
10,677
-11,694
-52% -$2.01M
PRQR icon
50
ProQR Therapeutics
PRQR
$243M
$710K 0.35%
230,770
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, DAFNA Capital Management held 85 positions worth $206M, up 11% from $186M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

DAFNA Capital Management withdrew a net $6.78M in Q1 2018, closing 10 positions and reducing 25 holdings. Its most notable exit was Voyager Therapeutics, an estimated $2.61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 83% a quarter earlier, followed by Financials.

Against the trend, DAFNA Capital Management opened a new position in Arena Pharmaceuticals Inc worth $5.01M.

  • DAFNA Capital Management's largest Q1 2018 buy was Arena Pharmaceuticals Inc: 126,742 shares worth $5.01M.
  • DAFNA Capital Management added most to Sage Therapeutics in Q1 2018, an estimated $11.1M increase.
  • DAFNA Capital Management's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $12.2M.
  • DAFNA Capital Management fully exited Voyager Therapeutics in Q1 2018, selling an estimated $2.61M.
  • DAFNA Capital Management's ten largest holdings make up 45% of its $206M portfolio in Q1 2018.
  • DAFNA Capital Management opened 12 new positions and closed 10 in Q1 2018.
  • DAFNA Capital Management's portfolio value rose 11% quarter-over-quarter to $206M.

Based on DAFNA Capital Management's 13F filing for Q1 2018, filed 15 May 2018.